Poolbeg Pharma has identified multiple new drug targets for the treatment of influenza. Previously, the identification of drug targets required manual analysis which took several years. Poolbeg is now exploring how to develop these new drug targets in order to generate value for shareholders. “Our collaboration with CytoReason has put Poolbeg at the forefront of AI drug discovery,” chief executive Jeremy Skillington said. RSV is a respiratory virus which usually causes mild, cold-like symptoms and inflames the smallest airways of the lungs.

Source: Irish Independent June 29, 2023 13:47 UTC